The Impact of Simvastatin on Lipidomic Markers of Cardiovascular Risk in Human Liver Cells Is Secondary to the Modulation of Intracellular Cholesterol

Statins are the first-line lipid-lowering therapy for reducing cardiovascular disease (CVD) risk. A plasma lipid ratio of two phospholipids, PI(36:2) and PC(18:0_20:4), was previously identified to explain 58% of the relative CVD risk reduction associated with pravastatin, independent of a change in...

Descripción completa

Detalles Bibliográficos
Autores principales: Schooneveldt, Yvette L., Giles, Corey, Keating, Michael F., Mellett, Natalie A., Jurrjens, Aaron W., Paul, Sudip, Calkin, Anna C., Meikle, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228384/
https://www.ncbi.nlm.nih.gov/pubmed/34070445
http://dx.doi.org/10.3390/metabo11060340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228384/
https://www.ncbi.nlm.nih.gov/pubmed/34070445
http://dx.doi.org/10.3390/metabo11060340

Ejemplares similares